Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 10/20 | 0.40 |
| ▸ | RAF1 | P04049 | 2/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 7/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20120236 | 0.93 | BRD9 (0.37) | BRD9RAF1CRBNEGFR | |
| SCHEMBL20120238 | 0.93 | BRD9 (0.37) | BRD9RAF1CRBNEGFR | |
| SCHEMBL29547535 | 0.93 | BRD9 (0.37) | BRD9RAF1CRBNEGFR | |
| SCHEMBL20132924 | 0.93 | BRD9 (0.45) | BRD9RAF1CRBNEGFRERBB2 | |
| SCHEMBL20120735 | 0.91 | BRD9 (0.45) | BRD9CRBNEGFRERBB2 | |
| SCHEMBL20129277 | 0.91 | BRD9 (0.45) | BRD9CRBNEGFRERBB2 | |
| SCHEMBL29547350 | 0.91 | BRD9 (0.45) | BRD9CRBNEGFRERBB2 | |
| SCHEMBL20132948 | 0.91 | BRD9 (0.45) | BRD9CRBNEGFRERBB2 | |
| SCHEMBL20120262 | 0.91 | BRD9 (0.39) | BRD9RAF1CRBNEGFR | |
| SCHEMBL20120714 | 0.91 | BRD9 (0.39) | BRD9RAF1CRBNEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | BRD9 1284/4885RAF1 974/4885CRBN 3/4885 |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | BRD9 1141/4885RAF1 966/4885CRBN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.